172 related articles for article (PubMed ID: 32569019)
21. Dyspareunia Related to GSM: Association of Total Vaginal Thickness via Transabdominal Ultrasound.
Balica AC; Cooper AM; McKevitt MK; Schertz K; Wald-Spielman D; Egan S; Bachmann GA
J Sex Med; 2019 Dec; 16(12):2038-2042. PubMed ID: 31542351
[TBL] [Abstract][Full Text] [Related]
22. Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders.
Erekson EA; Li FY; Martin DK; Fried TR
Menopause; 2016 Apr; 23(4):368-75. PubMed ID: 26645820
[TBL] [Abstract][Full Text] [Related]
23. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment.
Kao A; Binik YM; Amsel R; Funaro D; Leroux N; Khalifé S
J Sex Med; 2012 Aug; 9(8):2066-76. PubMed ID: 22621792
[TBL] [Abstract][Full Text] [Related]
24. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
25. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
Pup LD; Sánchez-Borrego R
Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
[TBL] [Abstract][Full Text] [Related]
26. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
27. The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study.
Palma F; Xholli A; Cagnacci A;
Maturitas; 2018 Feb; 108():18-23. PubMed ID: 29290210
[TBL] [Abstract][Full Text] [Related]
28. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
Bachmann GA; Komi JO;
Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
[TBL] [Abstract][Full Text] [Related]
29. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach.
Ettinger B; Hait H; Reape KZ; Shu H
Menopause; 2008; 15(5):885-9. PubMed ID: 18779677
[TBL] [Abstract][Full Text] [Related]
30. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
Panay N; Palacios S; Bruyniks N; Particco M; Nappi RE;
Maturitas; 2019 Jun; 124():55-61. PubMed ID: 31097180
[TBL] [Abstract][Full Text] [Related]
31. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
Vicariotto F; DE Seta F; Faoro V; Raichi M
Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
[TBL] [Abstract][Full Text] [Related]
32. Postpartum dyspareunia. An unexplored problem.
Goetsch MF
J Reprod Med; 1999 Nov; 44(11):963-8. PubMed ID: 10589408
[TBL] [Abstract][Full Text] [Related]
33. Female sexuality and vaginal health across the menopausal age.
Cagnacci A; Venier M; Xholli A; Paglietti C; Caruso S;
Menopause; 2020 Jan; 27(1):14-19. PubMed ID: 31738734
[TBL] [Abstract][Full Text] [Related]
34. The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause.
Particco M; Djumaeva S; Nappi RE; Panay N; Palacios S;
Menopause; 2020 Apr; 27(4):423-429. PubMed ID: 32068686
[TBL] [Abstract][Full Text] [Related]
35. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
[TBL] [Abstract][Full Text] [Related]
36. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
37. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
Davis SR; Robinson PJ; Jane F; White S; White M; Bell RJ
J Clin Endocrinol Metab; 2018 Nov; 103(11):4146-4154. PubMed ID: 30239842
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for Dyspareunia After First Childbirth.
Alligood-Percoco NR; Kjerulff KH; Repke JT
Obstet Gynecol; 2016 Sep; 128(3):512-518. PubMed ID: 27500349
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study.
Berreni N; Salerno J; Chevalier T; Alonso S; Mares P
BMC Womens Health; 2021 Aug; 21(1):322. PubMed ID: 34454465
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
J Sex Med; 2014 Feb; 11(2):487-97. PubMed ID: 24251418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
